Paul L. Berns, President and CEO at Anacor Pharmaceuticals, Inc. (ANAC), sold 20,000 shares at $138.40 ($2.8M) on 2015-08-13, disclosed to the SEC on 2015-08-17.
Scheduled sale ($2.8M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $136.49 | 1,655 | $226K | 8.1% |
| 2 | $137.52 | 3,489 | $480K | 17.3% |
| 3 | $138.40 | 3,281 | $454K | 16.4% |
| 4 | $139.45 | 11,575 | $1.6M | 58.2% |
| Total | $138.70 avg | 20,000 | $2.8M | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |